Logo

NIVFW

NewGenIvf Group Limited

NIVFW

NewGenIvf Group Limited • NASDAQ
$0.02 ▼ -10.31% (-0.00)
Market Cap $3.12 M
52w High $0.03
52w Low $0.02
Dividend Yield 0%
P/E 0
Volume 50
Outstanding Shares 156.18M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $1.274M ▼ $1.449M ▲ $-108K ▼ -8.477% ▼ $-4.75 ▼ $58.327K ▼
Q3-2024 $1.473M ▼ $429.898K ▼ $-19.857K ▲ -1.348% ▲ $-1.35 ▼ $226.87K ▼
Q4-2023 $1.519M $1.266M $-955K -62.851% $33.05 $451.847K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $457.74K ▲ $3.782M ▲ $5.06M ▼ $-844.614K ▲
Q3-2024 $169.661K ▲ $1.473M ▼ $8.548M ▲ $-6.585M ▼
Q4-2023 $54.104K ▼ $4.487M ▼ $1.241M ▼ $15.597M ▼
Q2-2023 $77.294K ▲ $38.673M ▼ $3.892M ▲ $34.781M ▼
Q4-2022 $54.719K $70.786M $2.465M $68.321M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-108.243K ▲ $-6.354M ▼ $13.588K ▼ $6.597M ▲ $288.079K ▲ $-6.357M ▼
Q4-2023 $-955.489K $-142.705K $18.373M $-18.227M $3.47K $-142.709K

Five-Year Company Overview

Income Statement

Income Statement The reported income statement shows almost no meaningful revenue yet and no clear pattern of profitability. Earnings per share have swung sharply from positive to negative, which likely reflects one‑off SPAC and accounting effects rather than a stable, operating business. In practical terms, this looks like a company still in transition: more of a development‑stage or restructuring story than a mature healthcare operator with steady clinic income. Any view of “earnings power” here is highly uncertain because the underlying operating results are not well established or clearly visible in the data provided.

Balance Sheet

Balance Sheet The balance sheet data provided are essentially blank, so it is hard to draw firm conclusions. That usually means investors need to look directly at recent filings to understand cash on hand, any SPAC trust proceeds, liabilities, and dilution potential from warrants and other securities. Conceptually, a company at this stage often relies heavily on equity capital and has limited tangible operating assets, but without reliable figures it is not possible to gauge balance‑sheet strength, leverage, or resilience through downturns. There is simply a high information gap here.

Cash Flow

Cash Flow The cash flow picture is also very thin, with only a small operating outflow reported and no visible investment spending. This is consistent with a business that is not yet generating material cash from operations and has not yet ramped up large‑scale capital investment. For investors, this usually means the company is still dependent on external financing and future execution of its strategy to fund growth. The path to self‑funding operations is not yet demonstrated, and the timing of any turn to sustainable positive cash flow is unclear.

Competitive Edge

Competitive Edge NewGenIvf’s competitive story rests far more on its positioning than on its current financials. Its main edge is the exclusive NewGenSort sperm‑sorting technology, backed by patents and specialized equipment. That creates a real barrier to entry in gender selection and certain genetic‑risk reduction applications. The company also has an established presence in parts of Asia that are important hubs for fertility tourism and legal surrogacy, with bundled services and “success guarantee” programs that differentiate it from standard IVF clinics. The planned shift to a licensing and royalty model could, if executed well, make the business more scalable and less capital‑intensive. Offsetting these strengths are meaningful risks: ethical and regulatory scrutiny around gender selection and surrogacy, intense competition from global fertility players, and the challenge of building brand trust in new markets like the United States from a relatively small base.

Innovation and R&D

Innovation and R&D Innovation is the core of this story. The company has acquired and rebranded a specialized cytometry‑based sperm‑sorting technology, giving it a unique tool that competitors may find hard to replicate quickly. It also holds several related patents and hardware systems that can be deployed or licensed to clinics. Management has signaled plans to build an in‑house research team, which could expand into areas like better embryo selection or genetic screening; however, these are forward‑looking goals rather than achievements today. At the same time, the company is branching into unrelated areas such as real estate and digital assets. While that may offer diversification, it can also dilute focus and strain management bandwidth away from the core fertility technology, where its true innovation edge appears to lie.

Summary

Overall, this looks like a very early‑stage, story‑driven healthcare technology play rather than a mature medical services company. The financial track record is thin, with minimal revenue, highly unstable earnings, and limited visibility on the balance sheet and cash flows. The real appeal, and risk, sit in the narrative: a potentially distinctive fertility‑technology platform with global licensing ambitions, layered on top of a niche IVF and surrogacy footprint in Asia, plus opportunistic moves into non‑core investments. Future outcomes will hinge on executing the NewGenSort rollout, navigating sensitive regulation and ethics, and proving that the business can convert its technology and clinics into durable, recurring cash flows. Until then, uncertainty is high and the profile is best understood as speculative and execution‑dependent rather than financially proven.